BioAtla (BCAB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BCAB BioAtla

Watchlist

2.070
+0.070+3.50%

Close Nov 5 16:00 ET

2.110
+0.040+1.93%

Pre 05:38 ET

100.05MMarket Cap-953P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: BioAtla to Report Financial Results Post-market on November 07
Moomoo NewsNov 1 21:00 ET
BioAtla, Inc. (NASDAQ:BCAB) Has Caught the Attention of Institutional Investors Who Hold a Sizeable 39% Stake
Yahoo FinanceOct 30 08:18 ET
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
Yahoo FinanceOct 9 17:57 ET
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
BenzingaOct 9 08:19 ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
BenzingaOct 2 12:31 ET
Express News | Bioatla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21St International Congress
ReutersOct 1 08:00 ET

Comments

Jaguar8

Oct 4 10:39

NEWS

$BioAtla (BCAB.US)$
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown ...

482829733727373

Oct 4 09:14

$BioAtla (BCAB.US)$ well well well good shorts

zyang_zy

Oct 2 11:17

Not sure what to do

$BioAtla (BCAB.US)$ any advice to hold or to sell???

Jaguar8

Sep 9 07:01

NEWS

$BioAtla (BCAB.US)$
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Mee...